Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentre, Uncontrolled, Phase Ib/II Study of LY2780301 in Combination With Weekly Paclitaxel in HER2-negative Metastatic or Locally Advanced Breast Cancer in Patients With and Without PI3/AKT/S6 Pathway Activation. - TAKTIC-IPC 2012-008

NCT01980277 is registered in ClinicalTrials.gov with Institut Paoli-Calmettes as lead sponsor.

NCT NCT01980277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01980277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentre, Uncontrolled, Phase Ib/II Study of LY2780301 in Combination With Weekly Paclitaxel in HER2-negative Metastatic or Locally Advanced Breast Cancer in Patients With and Without PI3/AKT/S6 Pathway Activation. - TAKTIC-IPC 2012-008
Lead sponsor
Institut Paoli-Calmettes
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2014
Completion date
December 12, 2018
Enrollment
68 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer